Opioids play a critical role in pain management for patients with hematologic malignancies, particularly during allogeneic hematopoietic cell transplantation (alloHCT). While the World Health Organization supports their use for moderate to severe …
Opioid Use Disorder (OUD) has become a critical public health issue in Kentucky, marked by a significant rise in opioid prescriptions and overdose deaths. The state reports one of the highest rates of opioid-related fatalities in the U.S., driven by …
The article discusses the significant impact of mood disorders, particularly major depressive disorder (MDD), on patients with epilepsy, noting that around 30% of epilepsy patients experience mood disorders—substantially higher than the general …
The opioid crisis is worsening, with a study in Maryland revealing that 20.6% of fentanyl overdose deaths from 2020 to 2023 were linked to xylazine, a potent contaminant. Xylazine-related deaths peaked in 2021, particularly affecting individuals aged …
The article discusses the alarming prevalence of substance use disorders (SUDs) among healthcare professionals (HCPs), with over 51.7% reporting lifetime illicit substance use. Commonly abused substances include alcohol, cannabis, and prescription …
Treatment-resistant depression (TRD) affects 30-40% of individuals with major depressive disorder, often failing to respond to traditional antidepressants. Ketamine, initially an anesthetic, has emerged as a rapid-acting antidepressant, showing …
The article discusses the key factors contributing to the escalating opioid use disorder (OUD) crisis, including over-prescription of opioids, socioeconomic challenges, mental health issues, cultural stigma surrounding addiction, and the …
The article discusses the therapeutic benefits of psychedelic drugs in mental health, highlighting their potential in treating conditions such as depression, PTSD, and alcoholism. Research demonstrates that psychedelics, including ketamine, MDMA, and …
The Complexity of Opioid Use Disorder Model (COUDM) provides a comprehensive framework for understanding Opioid Use Disorder (OUD), emphasizing the interplay of biological, psychological, and social factors that contribute to its complexity. Key …
The article discusses the crucial role of opioid agonists, such as methadone and buprenorphine, in managing opioid dependence and pain relief. Methadone is a full agonist providing effective pain relief and craving reduction, while buprenorphine is a …
The article discusses the multifaceted nature of opioid addiction and recovery, emphasizing biological, psychological, and social factors that influence addiction. Genetic predispositions can increase susceptibility to opioid dependence, while mental …
The article highlights the critical need for culturally relevant Opioid Use Disorder (OUD) treatment approaches, particularly for Indigenous populations in the U.S. Traditional treatment models often overlook the unique cultural values of these …
The article discusses the symptoms of depression in patients with epilepsy (PWE), highlighting that these symptoms can differ from those in the general population. Common symptoms include persistent sadness, loss of interest in activities, appetite …
Esketamine, approved by the FDA in 2019 for treatment-resistant depression (TRD), offers rapid relief from depressive symptoms and suicidal ideation, acting primarily as an NMDA receptor antagonist to enhance glutamate transmission and synaptic …
Treatment-Resistant Depression (TRD) is a significant challenge in psychiatric care, affecting a large portion of individuals diagnosed with Major Depressive Disorder (MDD). Defined as MDD that does not respond to at least two different classes of …
Methadone is a synthetic opioid crucial for treating opioid use disorder (OUD) through detoxification and maintenance therapy. It helps alleviate withdrawal symptoms and block euphoric effects of other opioids. Administered under certified healthcare …
The 4 panel drug test is a common screening tool used to detect substance abuse in workplaces, rehabilitation centers, and educational institutions. It identifies four major categories of drugs, typically including THC, cocaine, methamphetamine, and …
The article discusses the emergence of Auvelity, a novel antidepressant approved by the FDA for treating Major Depressive Disorder (MDD). Auvelity operates differently from traditional antidepressants by acting as an NMDA receptor antagonist, …
Postpartum depression (PPD) is a significant mental health issue affecting about 1 in 7 new mothers, characterized by symptoms such as persistent sadness, anxiety, and feelings of inadequacy. Hormonal changes post-childbirth, along with factors like …
Zuranolone, known as Zurzuvae, is a groundbreaking FDA-approved oral medication for postpartum depression (PPD) that can alleviate symptoms in as little as three days, with a typical treatment duration of two weeks. Unlike traditional antidepressants …
Opioid withdrawal is a challenging process that arises when an individual reduces or stops opioid use after prolonged use, leading to severe physiological and psychological symptoms such as anxiety, cravings, nausea, and pain. The onset and duration …
The article discusses the distressing flu-like symptoms associated with opiate withdrawal, which can include fever, chills, muscle aches, and fatigue. These symptoms often arise within hours to days after the last drug use, leading to potential …
The article discusses Zulresso (brexanolone), the first FDA-approved treatment specifically for severe postpartum depression (PPD). Affecting approximately 15% of women post-childbirth, PPD can lead to serious mood disturbances and bonding issues …
The article discusses the mechanism and evolving use of ketamine, an NMDA receptor antagonist, in treating Opioid Use Disorder (OUD). Initially developed as an anesthetic, ketamine is gaining traction for its rapid effects on cravings and withdrawal …
The article discusses Opioid Use Disorder (OUD), a serious health issue affecting millions globally, characterized by problematic opioid use resulting in significant distress and impairment. In the U.S., around 6.1 million people had OUD in 2022, …
The article discusses the clinical administration of ketamine, emphasizing that it should only be given in controlled environments by trained healthcare professionals to ensure patient safety and tailored treatment. Comprehensive psychological …
The article “Exploring Opioid Dependence: What You Need to Know” clarifies the distinction between opioid dependence and opioid use disorder (OUD). Opioid dependence is a physiological state where the body adapts to opioids, leading to …
The article discusses Adderall, a prescription medication used to treat ADHD and narcolepsy, and outlines important considerations for expecting mothers. Adderall, which contains amphetamine and dextroamphetamine, can have side effects such as lack …
Seroquel, or quetiapine, is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and as an adjunct for major depressive disorder. It works by affecting neurotransmitter receptors in the brain, balancing mood and reducing psychotic …
The article discusses the significance of mental health during pregnancy, highlighting that approximately 15% of pregnant women experience depression, which can lead to adverse maternal and fetal outcomes. Zoloft, a commonly prescribed …
The article outlines the phases of opioid withdrawal, highlighting the initial phase that starts 6 to 12 hours post-last dose, characterized by mild symptoms like anxiety and sweating. Symptoms peak between 24 to 72 hours, becoming severe with nausea …
The article “Understanding Wellbutrin: What You Need to Know Before Pregnancy” discusses the use of Wellbutrin, a norepinephrine-dopamine reuptake inhibitor, primarily for treating major depressive disorder and seasonal affective …
